Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator

Youwen Chen, Rui Liu, Chenxi Li, Yurong Song, Guangzhi Liu, Qingcai Huang, Liuchunyang Yu, Dongjie Zhu, Cheng Lu*, Aiping Lyu*, Linfu Li*, Yuanyan Liu*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Paclitaxel is a widely used anti-tumor chemotherapeutic drug. Solvent-based paclitaxel causes bone marrow suppression, allergic reactions, neurotoxicity and systemic toxicity, which are associated with non-specific cytotoxicity and side effects of fat-soluble solvents. Studies have explored various new nano-drug strategies of paclitaxel, including nanoparticle albumin-bound paclitaxel (nab-paclitaxel) to improve the water solubility and safety of paclitaxel. Nab-paclitaxel is a targeted solvent-free formulation that inhibits microtubule depolymerization to anticancer. It is easily taken up by tumor and immune cells owing to the nano-scaled size and superior biocompatibility. The internalized nab-paclitaxel exhibits significant immunostimulatory activities to promote cancer-immunity cycle. The aim of this study was to explore the synergistic effect of nab-paclitaxel in tumor antigen presentation, T cell activation, reversing the immunosuppressive pattern of tumor microenvironment (TME), and the synergistic effect with cytotoxic lymphocytes (CTLs) in clearance of tumor cells. The effects of nab-paclitaxel on modulation of cancer-immunity cycle, provides potential avenues for combined therapeutic rationale to improve efficacy of immunotherapy.

Original languageEnglish
Pages (from-to)3445-3460
Number of pages16
JournalAmerican Journal of Cancer Research
Issue number7
Publication statusPublished - 30 Jul 2021

User-Defined Keywords

  • Nab-paclitaxel
  • cancer-immunity cycle
  • immunomodulatory
  • anti-tumor


Dive into the research topics of 'Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator'. Together they form a unique fingerprint.

Cite this